Operator: Good morning, ladies and gentlemen, and welcome to Scholar Rock’s Third Quarter 2025 Conference Call. [Operator ...
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results
Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrol ...
Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrol ...
There are gifts, and then there are gifts, the ones inventive enough to surprise and delight the recipient. Some are fun; ...
In both fatal cases, patients developed markedly elevated liver enzymes and required hospitalization within two months of Elevidys infusion. An additional serious, non-fatal case of acute liver injury ...
The U.S. Food and Drug Administration said on Friday it approved new labeling for Sarepta Therapeutics' gene therapy Elevidys ...
A gene therapy for Duchenne muscular dystrophy caused complications to the liver, prompting a review of its use for younger patients.
November 14, 2025) – Damon Inc. (OTCID: DMNIF) (“Damon” or the “Company”), a designer and developer of electric motorcycles and other personal mobility products that seek to empower the personal ...
The U.S. Food and Drug Administration announced it is taking action to approve new labeling submitted by the company that includes the addition of ...
The stock market is starting to look rocky. It seems like a perfect opportunity to play defense with exchange-traded funds ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback